EGFR and non-small cell lung carcinoma: Here, in this short report, we present a female case diagnosed with advanced NSCLC with L858R mutation in EGFR, which has presented grade 3 cardiac failure after being treated with osimertinib for 6 months; we successfully relieved the symptoms after switching the treatment with alternative third-generation EGFR-TKI aumolertinib.